Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
  • Phase

    Phase 1/Phase 2
  • Study Type

  • Status

    Active, not recruiting
  • Study Participants

The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).
This is a Phase 1/2, first-in-human, multicenter, open-label, single arm dose escalation trial of XC001. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ascending dose groups, followed by an expansion of the highest tolerated dose with 32 additional subjects. XC001 will be administered by a transthoracic epicardial procedure. Safety will be the focus for the initial 6 months after XC001 administration followed by one safety focused telephone evaluation at Month 12.
Study Started
Jan 24
Primary Completion
Jan 31
Study Completion
Jul 30
Last Update
Jul 08

Biological AdVEGFXC1

AdVEGFXC1 at one of 4 doses

  • Other names: XC001

AdVEGFXC1 at 1x10^9 vp Experimental

AdVEGFXC1 at 1x10^10 vp Experimental

AdVEGFXC1 at 4x10^10 vp Experimental

AdVEGFXC1 at 1x10^11 vp Experimental


Inclusion Criteria:

Males and females, age 18 to 80 years
Diagnosis of chronic angina due to obstructive coronary artery disease that is refractory to drug therapy and unsuitable for revascularization via coronary artery bypass graft or percutaneous coronary intervention
Angina class II-IV based on Canadian Cardiovascular Society Classification of Angina Pectoris
Adequate hematologic (hemoglobin ≥ 10 g/dL, absolute neutrophil count > 1.2 × 10^3 per μL and platelet count ≥ 75,000 per μL), hepatic (alanine aminotransferase and aspartate aminotransferase ≤ 3 x ULN; total bilirubin ≤ 2 x ULN), and renal function (glomerular filtration rate > 29 mL/minute/1.73 m2)
Adequate birth control if of child-bearing potential
Must be willing and able to provide informed consent

Exclusion Criteria:

ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI) not requiring revascularization, transmural myocardial infarction or cerebral vascular accident within the past 30 days
New York Heart Association Function Class III or IV or left ventricular ejection fraction < 25% within the 6 weeks prior to the screening visit
HbA1c ≥ 8.5%, SBP <90 or >180 mmHg, DBP >100 mmHg
Other concurrent medical conditions that could jeopardize the safety of the subject or objectives of the study
No Results Posted